G1 Therapeutics, Inc., is a clinical-stage biopharmaceutical company focused on the discovery, development and delivery of innovative therapies that improve the lives of those affected by cancer. The company is currently advancing three clinical-stage oncology programs. Two of our product candidates, trilaciclib and lerociclib, have broad therapeutic potential and may serve as backbone therapies for multiple combination regimens. Our third product candidate, G1T48, is a potential best-in-class oral selective estrogen receptor degrader, or SERD, which is targeted for the treatment of estrogen receptor-positive (ER+) breast cancer. All three investigational therapies have the potential to become new standards of care for women living with breast cancer and provide benefit at early stages of their disease, including in the adjuvant setting. G1 owns or holds an exclusive license for worldwide commercial rights to each of its product candidates. Source
No articles found.
H&G Science aims to facilitate the safe and effective treatment of diseases. Our g...
H&G Science aims to facilitate the safe and eff...
Iterum Therapeutics plc is an Ireland-based clinical-stage pharmaceutical company ...
Iterum Therapeutics plc is an Ireland-based cli...
Lipocine Inc. is a clinical-stage biopharmaceutical company focused on metabolic a...
Lipocine Inc. is a clinical-stage biopharmaceut...
Together, a potent new drug and a blood test to guide its use can be a life change...
Together, a potent new drug and a blood test to...
Oncolytics is focused on obtaining regulatory approval for pelareorep for metastat...
Oncolytics is focused on obtaining regulatory a...
We discover and develop medicines to defeat neurodegeneration. The science is brea...
We discover and develop medicines to defeat neu...
Midatech is an international specialty pharmaceutical company focused on the devel...
Midatech is an international specialty pharmace...
Join the National Investor Network and get the latest information with your interests in mind.